Chemocentryx Inc (CCXI) 5.39 $CCXI
ChemoCentryx Announces Financial Results for the First Quarter Ended March 31, 2014
GlobeNewswire - Thu May 08, 3:48PM CDT
ChemoCentryx, Inc., (Nasdaq:CCXI), a clinical-stage biopharmaceutical company focused on autoimmune diseases, inflammatory disorders and cancer, announced today its financial results for the first quarter ended March 31, 2014.
Crohn's Disease - Pipeline Review, H1 2014: 83 Companies and 120 Drugs Profiled
M2 - Thu May 08, 5:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/f8cqn8/crohns_disease) has announced the addition of the "Crohn's Disease - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Crohn's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Crohn's Disease and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Crohn's Disease - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Crohn's Disease and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Crohn's Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects Companies Involved: - 4SC AG - AbGenomics International, Inc. - AbbVie Inc. - Advancell - Alba Therapeutics Corporation - Alfa Wassermann S.p.A - Allozyne, Inc. - AlphaMab Co., Ltd - Altheus Therapeutics, Inc. - Amgen Inc. - Ampio Pharmaceuticals, Inc. - Amunix, Inc. - Aniona ApS - Antibe Therapeutics, Inc. - Aprogen, Inc. - AstraZeneca PLC - BioLineRx, Ltd. - Biocon Limited - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - CIMAB S.A. - CLL Pharma - Calypso Biotech SA - Celgene Corporation - Celltrion, Inc. - ChemoCentryx, Inc. - ChironWells GmbH - Curaxys, S.L. - Daiichi Sankyo Company, Limited - Effimune SAS Drug Profiles: - vedolizumab - infliximab biosimilar - infliximab biosimilar - remestemcel-L - vedolizumab - adalimumab - ustekinumab - vercirnon sodium - infliximab - budesonide ER - (rifabutin clarithromycin clofazimine) - infliximab biosimilar - adalimumab biosimilar - rifaximin - laquinimod sodium - tofacitinib - eldelumab - cenplacel-L - PF-04236921 - teduglutide - TNF-Kinoid - AbGn-168H - foralumab - mercaptopurine - adalimumab - vidofludimus - OvaSave - GED-0301 - zucapsaicin - Alequel For more information visit http://www.researchandmarkets.com/research/f8...ns_disease
Diabetic Nephropathy - Pipeline Review, H1 2014: 37 Companies and 58 Drugs Profiled
M2 - Thu May 08, 3:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/x6n63h/diabetic) has announced the addition of the "Diabetic Nephropathy - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Nephropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Nephropathy and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Diabetic Nephropathy - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Diabetic Nephropathy and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Diabetic Nephropathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Involved: - AbbVie Inc. - Ampio Pharmaceuticals, Inc. - Angelini Group - Astellas Pharma Inc. - Bayer AG - CCRP Therapeutics GmbH - ChemoCentryx, Inc. - Chong Kun Dang Pharmaceutical Corp. - Concert Pharmaceuticals, Inc. - Cyano Biotech GmbH - Daiichi Sankyo Company, Limited - Dongwha Pharm Co., Ltd. - Eli Lilly and Company - Emergent BioSolutions Inc. - Fibrotech Therapeutics Pty. Ltd. - GNI Group Ltd. - Galectin Therapeutics - GenKyoTex S.A. - Gentium S.p.A. - Glucox Biotech AB - IMMD Inc. - Intercept Pharmaceuticals, Inc. - Inventiva SAS - Johnson & Johnson - Mesoblast Limited - Mitsubishi Pharmaceutical Corporation - Mitsubishi Tanabe Pharma Corporation - NephroGenex, Inc. - Noxxon Pharma AG Drug Profiles: - canagliflozin - atrasentan hydrochloride - baricitinib - NOX-E-36 - IMD-1041 - CS-3150 - DW-1029M - GKT-137831 - PF-00489791 - CCX-140 - LY-2382770 - bindarit - Colchicine - probucol - PF-04634817 - Pyridoxamine Dihydrochloride - GLY-230 - corticotropin - CTP-499 - MT-3995 - finerenone - cilostazol - PHN-033 - CKD-322 - Allogeneic Mesenchymal Precursor Cells For Diabetic Nephropathy - LY-3016859 - FT-011 - ASP-8232 - pirfenidone - THR-123 For more information visit http://www.researchandmarkets.com/research/x6n63h/diabetic
Commit To Buy ChemoCentryx At $5, Earn 23.8% Annualized Using Options
StockOptionsChannel.com - Wed May 07, 10:38AM CDT
Investors eyeing a purchase of ChemoCentryx, Inc. shares, but tentative about paying the going market price of $5.60/share, might benefit from considering selling puts among the alternative strategies at their disposal.
3 Stocks Under $10 Moving Higher
at The Street - Fri May 02, 7:08AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
ChemoCentryx to Hold First Quarter 2014 Financial Results Conference Call on Thursday, May 8, 2014
GlobeNewswire - Tue Apr 29, 9:29AM CDT
ChemoCentryx, Inc. (Nasdaq:CCXI) announced today that the Company's first quarter 2014 financial results will be released after market close on Thursday, May 8, 2014. ChemoCentryx executive management will host a conference call beginning at 5:00 p.m. Eastern Time on May 8, 2014, to discuss these results and to answer questions.
Global Kidney Disease Therapeutics Pipeline Review 2014 - Analysis of 22 Companies & 32 Drug Profiles
M2 - Mon Apr 28, 5:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ls4c8m/kidney_disease) has announced the addition of the "Kidney Disease - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Kidney Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Kidney Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Kidney Disease - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Kidney Disease and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Kidney Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Kidney Disease pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Sanofi - Nektar Therapeutics - Chugai Pharmaceutical Co., Ltd. - LEO Pharma A/S - Teva Pharmaceutical Industries Limited - Zydus Cadila Healthcare Limited - Gentium S.p.A. - Celldex Therapeutics, Inc. - Osteologix Holdings Plc. - Ahn-Gook Pharmaceutical Co., Ltd. - DiaMedica Inc. - Upsher-Smith Laboratories, Inc. - TetraLogic Pharmaceuticals - ChemoCentryx, Inc. - Anexon, Inc. - Otsuka Holdings Co., Ltd. - BIOPROJET SCR - Advicenne Pharma - ZS Pharma, Inc. - G1 Therapeutics, Inc. - AbbVie Inc. Drug Profiles - ADV-7809 - benazepril hydrochloride - ADV-7103 - tolvaptan - methylprednisolone - ZS-9 - AGNPN-803 - hydrocodone bitartrate ER - LEO-27847 - DM-199 - tiprolisant - CCX-872 - RG-7641 - CDX-1189 - CU-NP - Necrostatin Program - Oligotide - NKTR-228 - CCR2 Antagonist - CH-5451098 - SkQR-1 - TNT-009 - SLR-080811 Derivative - AVE-0991 - NBS-101 - Prod-1 - messenger RNA Therapeutics Program - AHRO-200 - CDK-4/6 Inhibitors As Renal Protectants - A77-Based Monobody For more information visit http://www.researchandmarkets.com/research/ls...ey_disease
Why You Shouldn't Bet Against ChemoCentryx (CCXI) Stock - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 7:59AM CDT
One stock that might be an intriguing choice for investors right now is ChemoCentryx
Nasdaq stocks posting largest percentage decreases
AP - Thu Apr 10, 12:34PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
ChemoCentryx Appoints Anne-Marie S. Duliege, M.D., M.S. to Chief Strategic Development Role and Head of Immuno-Oncology
GlobeNewswire - Thu Mar 27, 7:30AM CDT
ChemoCentryx, Inc., (Nasdaq:CCXI), a clinical-stage biopharmaceutical company focused on autoimmune diseases, inflammatory disorders and cancer, announced today that it has appointed Anne-Marie S. Duliege, M.D., M.S., to a newly created position within the Company. Effective immediately, Dr. Duliege will be acting as Executive Vice President, Chief of Strategic Development and Head of Immuno-oncology.
ChemoCentryx (CCXI) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 20, 7:36AM CDT
ChemoCentryx (CCXI) Shares March Higher, Can It Continue?
ChemoCentryx (CCXI) Jumps: Stock Rises 9.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 19, 7:51AM CDT
ChemoCentryx, Inc. was a big mover last session, as its shares rose nearly 10% on the day.
ChemoCentryx Announces Financial Results for the Quarter and Year Ended December 31, 2013
GlobeNewswire - Thu Mar 13, 3:05PM CDT
ChemoCentryx, Inc., (Nasdaq:CCXI), a clinical-stage biopharmaceutical company focused on autoimmune diseases, inflammatory disorders and cancer, announced today its financial results for the fourth quarter and year ended December 31, 2013.
ChemoCentryx to Hold Fourth Quarter and Year-End 2013 Financial Results Conference Call on Thursday, March 13, 2014
GlobeNewswire - Mon Mar 03, 7:30AM CST
ChemoCentryx, Inc. (Nasdaq:CCXI) announced today that the Company's fourth quarter and year-end 2013 financial results will be released after market close on Thursday, March 13, 2014. ChemoCentryx executive management will host a conference call beginning at 5:00 p.m. Eastern Time on March 13, 2014, to discuss these results and to answer questions.
ChemoCentryx to Present at the Cowen and Company 34th Annual Health Care Conference
GlobeNewswire - Tue Feb 25, 9:28AM CST
ChemoCentryx, Inc. (Nasdaq:CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the Cowen and Company 34 Annual Health Care Conference on Tuesday, March 4, 2014, at 10:40 a.m. Eastern Time at The Boston Marriott Copley Place hotel in Boston, MA.
5 Stocks Poised for Breakouts
at The Street - Fri Feb 21, 12:53PM CST
These stocks look ready to break out and trade higher from current levels.
5 Under-$10 Biotech Stocks to Watch
at The Street - Fri Jan 10, 6:00AM CST
Keep these biotech stocks on your radar.
ChemoCentryx Announces Financial Results for the First Quarter Ended March 31, 2014
GlobeNewswire - Thu May 08, 3:48PM CDT
ChemoCentryx, Inc., (Nasdaq:CCXI), a clinical-stage biopharmaceutical company focused on autoimmune diseases, inflammatory disorders and cancer, announced today its financial results for the first quarter ended March 31, 2014.
Crohn's Disease - Pipeline Review, H1 2014: 83 Companies and 120 Drugs Profiled
M2 - Thu May 08, 5:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/f8cqn8/crohns_disease) has announced the addition of the "Crohn's Disease - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Crohn's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Crohn's Disease and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Crohn's Disease - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Crohn's Disease and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Crohn's Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects Companies Involved: - 4SC AG - AbGenomics International, Inc. - AbbVie Inc. - Advancell - Alba Therapeutics Corporation - Alfa Wassermann S.p.A - Allozyne, Inc. - AlphaMab Co., Ltd - Altheus Therapeutics, Inc. - Amgen Inc. - Ampio Pharmaceuticals, Inc. - Amunix, Inc. - Aniona ApS - Antibe Therapeutics, Inc. - Aprogen, Inc. - AstraZeneca PLC - BioLineRx, Ltd. - Biocon Limited - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - CIMAB S.A. - CLL Pharma - Calypso Biotech SA - Celgene Corporation - Celltrion, Inc. - ChemoCentryx, Inc. - ChironWells GmbH - Curaxys, S.L. - Daiichi Sankyo Company, Limited - Effimune SAS Drug Profiles: - vedolizumab - infliximab biosimilar - infliximab biosimilar - remestemcel-L - vedolizumab - adalimumab - ustekinumab - vercirnon sodium - infliximab - budesonide ER - (rifabutin clarithromycin clofazimine) - infliximab biosimilar - adalimumab biosimilar - rifaximin - laquinimod sodium - tofacitinib - eldelumab - cenplacel-L - PF-04236921 - teduglutide - TNF-Kinoid - AbGn-168H - foralumab - mercaptopurine - adalimumab - vidofludimus - OvaSave - GED-0301 - zucapsaicin - Alequel For more information visit http://www.researchandmarkets.com/research/f8...ns_disease
Diabetic Nephropathy - Pipeline Review, H1 2014: 37 Companies and 58 Drugs Profiled
M2 - Thu May 08, 3:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/x6n63h/diabetic) has announced the addition of the "Diabetic Nephropathy - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Nephropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Nephropathy and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Diabetic Nephropathy - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Diabetic Nephropathy and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Diabetic Nephropathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Involved: - AbbVie Inc. - Ampio Pharmaceuticals, Inc. - Angelini Group - Astellas Pharma Inc. - Bayer AG - CCRP Therapeutics GmbH - ChemoCentryx, Inc. - Chong Kun Dang Pharmaceutical Corp. - Concert Pharmaceuticals, Inc. - Cyano Biotech GmbH - Daiichi Sankyo Company, Limited - Dongwha Pharm Co., Ltd. - Eli Lilly and Company - Emergent BioSolutions Inc. - Fibrotech Therapeutics Pty. Ltd. - GNI Group Ltd. - Galectin Therapeutics - GenKyoTex S.A. - Gentium S.p.A. - Glucox Biotech AB - IMMD Inc. - Intercept Pharmaceuticals, Inc. - Inventiva SAS - Johnson & Johnson - Mesoblast Limited - Mitsubishi Pharmaceutical Corporation - Mitsubishi Tanabe Pharma Corporation - NephroGenex, Inc. - Noxxon Pharma AG Drug Profiles: - canagliflozin - atrasentan hydrochloride - baricitinib - NOX-E-36 - IMD-1041 - CS-3150 - DW-1029M - GKT-137831 - PF-00489791 - CCX-140 - LY-2382770 - bindarit - Colchicine - probucol - PF-04634817 - Pyridoxamine Dihydrochloride - GLY-230 - corticotropin - CTP-499 - MT-3995 - finerenone - cilostazol - PHN-033 - CKD-322 - Allogeneic Mesenchymal Precursor Cells For Diabetic Nephropathy - LY-3016859 - FT-011 - ASP-8232 - pirfenidone - THR-123 For more information visit http://www.researchandmarkets.com/research/x6n63h/diabetic
Commit To Buy ChemoCentryx At $5, Earn 23.8% Annualized Using Options
StockOptionsChannel.com - Wed May 07, 10:38AM CDT
Investors eyeing a purchase of ChemoCentryx, Inc. shares, but tentative about paying the going market price of $5.60/share, might benefit from considering selling puts among the alternative strategies at their disposal.
3 Stocks Under $10 Moving Higher
at The Street - Fri May 02, 7:08AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
ChemoCentryx to Hold First Quarter 2014 Financial Results Conference Call on Thursday, May 8, 2014
GlobeNewswire - Tue Apr 29, 9:29AM CDT
ChemoCentryx, Inc. (Nasdaq:CCXI) announced today that the Company's first quarter 2014 financial results will be released after market close on Thursday, May 8, 2014. ChemoCentryx executive management will host a conference call beginning at 5:00 p.m. Eastern Time on May 8, 2014, to discuss these results and to answer questions.
Global Kidney Disease Therapeutics Pipeline Review 2014 - Analysis of 22 Companies & 32 Drug Profiles
M2 - Mon Apr 28, 5:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ls4c8m/kidney_disease) has announced the addition of the "Kidney Disease - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Kidney Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Kidney Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Kidney Disease - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Kidney Disease and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Kidney Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Kidney Disease pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Sanofi - Nektar Therapeutics - Chugai Pharmaceutical Co., Ltd. - LEO Pharma A/S - Teva Pharmaceutical Industries Limited - Zydus Cadila Healthcare Limited - Gentium S.p.A. - Celldex Therapeutics, Inc. - Osteologix Holdings Plc. - Ahn-Gook Pharmaceutical Co., Ltd. - DiaMedica Inc. - Upsher-Smith Laboratories, Inc. - TetraLogic Pharmaceuticals - ChemoCentryx, Inc. - Anexon, Inc. - Otsuka Holdings Co., Ltd. - BIOPROJET SCR - Advicenne Pharma - ZS Pharma, Inc. - G1 Therapeutics, Inc. - AbbVie Inc. Drug Profiles - ADV-7809 - benazepril hydrochloride - ADV-7103 - tolvaptan - methylprednisolone - ZS-9 - AGNPN-803 - hydrocodone bitartrate ER - LEO-27847 - DM-199 - tiprolisant - CCX-872 - RG-7641 - CDX-1189 - CU-NP - Necrostatin Program - Oligotide - NKTR-228 - CCR2 Antagonist - CH-5451098 - SkQR-1 - TNT-009 - SLR-080811 Derivative - AVE-0991 - NBS-101 - Prod-1 - messenger RNA Therapeutics Program - AHRO-200 - CDK-4/6 Inhibitors As Renal Protectants - A77-Based Monobody For more information visit http://www.researchandmarkets.com/research/ls...ey_disease
Why You Shouldn't Bet Against ChemoCentryx (CCXI) Stock - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 7:59AM CDT
One stock that might be an intriguing choice for investors right now is ChemoCentryx
Nasdaq stocks posting largest percentage decreases
AP - Thu Apr 10, 12:34PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
ChemoCentryx Appoints Anne-Marie S. Duliege, M.D., M.S. to Chief Strategic Development Role and Head of Immuno-Oncology
GlobeNewswire - Thu Mar 27, 7:30AM CDT
ChemoCentryx, Inc., (Nasdaq:CCXI), a clinical-stage biopharmaceutical company focused on autoimmune diseases, inflammatory disorders and cancer, announced today that it has appointed Anne-Marie S. Duliege, M.D., M.S., to a newly created position within the Company. Effective immediately, Dr. Duliege will be acting as Executive Vice President, Chief of Strategic Development and Head of Immuno-oncology.
ChemoCentryx (CCXI) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 20, 7:36AM CDT
ChemoCentryx (CCXI) Shares March Higher, Can It Continue?
ChemoCentryx (CCXI) Jumps: Stock Rises 9.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 19, 7:51AM CDT
ChemoCentryx, Inc. was a big mover last session, as its shares rose nearly 10% on the day.
ChemoCentryx Announces Financial Results for the Quarter and Year Ended December 31, 2013
GlobeNewswire - Thu Mar 13, 3:05PM CDT
ChemoCentryx, Inc., (Nasdaq:CCXI), a clinical-stage biopharmaceutical company focused on autoimmune diseases, inflammatory disorders and cancer, announced today its financial results for the fourth quarter and year ended December 31, 2013.
ChemoCentryx to Hold Fourth Quarter and Year-End 2013 Financial Results Conference Call on Thursday, March 13, 2014
GlobeNewswire - Mon Mar 03, 7:30AM CST
ChemoCentryx, Inc. (Nasdaq:CCXI) announced today that the Company's fourth quarter and year-end 2013 financial results will be released after market close on Thursday, March 13, 2014. ChemoCentryx executive management will host a conference call beginning at 5:00 p.m. Eastern Time on March 13, 2014, to discuss these results and to answer questions.
ChemoCentryx to Present at the Cowen and Company 34th Annual Health Care Conference
GlobeNewswire - Tue Feb 25, 9:28AM CST
ChemoCentryx, Inc. (Nasdaq:CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the Cowen and Company 34 Annual Health Care Conference on Tuesday, March 4, 2014, at 10:40 a.m. Eastern Time at The Boston Marriott Copley Place hotel in Boston, MA.
5 Stocks Poised for Breakouts
at The Street - Fri Feb 21, 12:53PM CST
These stocks look ready to break out and trade higher from current levels.
5 Under-$10 Biotech Stocks to Watch
at The Street - Fri Jan 10, 6:00AM CST
Keep these biotech stocks on your radar.
